American Capital: Surging NAV With More Upside Potential [View article]
In addition to being significantly accretive to NAV, the buyback is really helping NOI/share, another important BDC metric, the one that helps pay the future dividends. I'm too lazy to look up at the moment and calculate the improvement in NOI/share over the last 6 quarters, but it has been pretty substantial, and will only increase the amounts of future dividends/share...
Discovery Laboratories: Innovative Financing Is A Catalyst To Buy The Stock [View article]
This is indeed a nifty financing arrangement. But Deerfield always has their own interests in mind, and they ALWAYS extract their pound of flesh. This is an interesting story that I will continue to follow.
Pengrowth Energy Goes All In On Lindbergh [View article]
I agree Bluesmoke. With a yield of 10%, the market is pricing in a cut. Might as well do it now and get it over with, and save some capital. Management in my opinion is honest about the timetable and economics, but #$%% happens sometime in the drilling business and having some extra capital around may save dilution in the future.
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
The answer is not yes (yet). Look at the data from the HIV trial. The patients had undetectable viral load, went off HAART, the load spikes, and then took SGMO's treatment. In 1 case (the CCR5 heterozygote) the viral load did return to undetectable levels, but not in the others. While the T-cells persist, there aren't enough of them as of yet.
Growing Use Of Radiopharmaceuticals For Fighting Cancer Shows Promise [View article]
With respect to SPPI, Zevalin is a great drug, but the sales just haven't gone anywhere. Even with the bioscan removal, and now with a sales revamping, I'm slightly sketpcal whether or not they can get past the current ~30 MM (if my memory serves) a year in sales. It is too bad, Zevalin is a great therapy and was shown in head to head trials to be superior to Rituxan in the refractory setting.
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
I think it would be very prudent for SGMO to raise cash above 9$/share before data comes out. I like the company and I like their chances in HIV, its just the valuation has gotten quite rich, that's all.
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
With the huge runup in share price, I wouldn't be surprised if SGMO raises additional capital. Also, I think there may be a "buy the rumor sells the news." If the trial data is indeed extremely positive, I'll gladly buy back into the stock, even at 2x these levels. But the current valuation of ~0.5 BB for a single therapeutic at this stage is simply not justified.
Seadrill: Pacific Drilling May Be Hard To Swallow With Money From Tender Rig Deal [View article]
It's only dilution if they pay too much! If the return on the invested capital (additional equity in this case) is greater than the cost of the equity capital, it's not dilution.
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
Seems like I am following all of your articles Smith! So I've been following the SGMO story for ~2 years now and recently sold out of my position. I think the valuation is getting a bit high here when there is still the million dollar question: can SGMO modify enough cells to get the functional cure for HIV? Remember, this is the ONLY clinical candidate SGMO has. As much as I like the partnership with Shire, its all preclinical at this point.
Seadrill: Pacific Drilling May Be Hard To Swallow With Money From Tender Rig Deal [View article]
Interesting article. It would definitely be a large acquisition and a big one for SDRL to digest. What about issuing equity though? Isn't that a possibility?
Seattle Genetics Shares Continue To Impress - And It's Not Too Late To Buy [View article]
Annaly Capital: This Positive News Could Mean A Dividend Hike [View article]
American Capital: Surging NAV With More Upside Potential [View article]
Discovery Laboratories: Innovative Financing Is A Catalyst To Buy The Stock [View article]
The S&P 500 Settles Into A Narrow Dividend Yield Range: What It Means For Investors [View article]
Pengrowth Energy Goes All In On Lindbergh [View article]
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
Growing Use Of Radiopharmaceuticals For Fighting Cancer Shows Promise [View article]
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
2 big sells
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
Seadrill: Pacific Drilling May Be Hard To Swallow With Money From Tender Rig Deal [View article]
Sangamo: Paradigm-Shifting Approach To Gene Altering Leads To Unique Product Opportunities [View article]
Arena Stumbles On EMA Concerns Over Belviq Ahead Of Launch [View article]
Seadrill: Pacific Drilling May Be Hard To Swallow With Money From Tender Rig Deal [View article]